OncoMatch/Clinical Trials/NCT06464861
Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma
Is NCT06464861 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies CD19-CAR-NK/T for primary mediastinal b-cell lymphoma (pmbcl).
Treatment: CD19-CAR-NK/T — To study the safety and efficacy of cord blood-derived CD19 CAR-NK cells sequential with 7x19 CAR-T in relapse / refractory B cell lymphoma
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Biomarker criteria
Required: CD19 expression (positive)
The puncture section of the tumor tissue was positive for CD19 expression
Required: CD20 wild-type
Previous treatment must include CD20 monoclonal antibody treatment (unless the subject is CD20 negative)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: cd20 monoclonal antibody
Must have received: anthracycline
Cannot have received: gene therapy
Lab requirements
Kidney function
Creatinine clearance rate (Cockcroft-Gault method) ≥60 mL/min; Glomerular filtration rate >50 mL/min
Liver function
Alanine aminotransferase, aspartate aminotransferase ≤ 2.5× UNL; Serum total bilirubin and alkaline phosphatase ≤1.5× UNL
Cardiac function
Cardiac ejection fraction (EF) ≥50%; Subjects with Grade III or IV cardiac dysfunction according to the New York Heart Association's cardiac function grading criteria [excluded]
Sufficient organ function reserve: Alanine aminotransferase, aspartate aminotransferase ≤ 2.5× UNL; Creatinine clearance rate (Cockcroft-Gault method) ≥60 mL/min; Serum total bilirubin and alkaline phosphatase ≤1.5× UNL; Glomerular filtration rate >50 mL/min; Cardiac ejection fraction (EF) ≥50%; Under natural indoor air environment, basic oxygen saturation >92%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06464861 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior gene therapy disqualifies patients from enrollment.
Does this trial require CD19?
Yes, CD19 expression is a required biomarker for enrollment.
Does this trial require CD20?
Yes, CD20 wild-type is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify